AD NUMBER

ADB224562

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Aug 96. Other requests shall be referred to Commander, Army Medical Research and Materiel Command, Attn: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

AUTHORITY

USAMRMC Ltr., 6 My 98

AD_____

GRANT NUMBER DAMD17-94-J-4172

TITLE: Role of Raf-1 Signaling in Breast Cancer - Progression to Estrogen Independent Growth

PRINCIPAL INVESTIGATOR: Dorraya El-Ashry, Ph.D.

CONTRACTING ORGANIZATION: Georgetown University
                           Washington, DC 20057

REPORT DATE: July 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
              U.S. Army Medical Research and Materiel Command
              Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S.
Government agencies only (proprietary information, Jul 96).
Other requests for this document shall be referred to Commander,
U.S. Army Medical Research and Materiel Command, ATTN:
MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

DTIC QUALITY INSPECTED 4

19970605 131

REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE July 1996	3. REPORT TYPE AND DATES COVERED Annual (15 Jun 95 - 14 Jun 96)	
4. TITLE AND SUBTITLE Role of Raf-1 Signaling in Breast Cancer - Progression to Estrogen Independent Growth		**5. FUNDING NUMBERS** DAMD17-94-J-4172	
6. AUTHOR(S) Dorraya El-Ashry, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057		**8. PERFORMING ORGANIZATION REPORT NUMBER**	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick Frederick, Maryland 21702-5012		**10. SPONSORING/MONITORING AGENCY REPORT NUMBER**	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Aug 96). Other requests for this document shall be referred to Commander, U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012		**12b. DISTRIBUTION CODE**	

13. ABSTRACT *(Maximum 200*

In order to study the role of Raf-1 kinase signaling in the progression of breast cancer from estrogen-dependent to estrogen-independent growth, we had previously established several clones of MCF-7 cells stably expressing a truncated, constitutively active Raf and examined these clones for their ability to grow in the absence of estrogen. Constitutive activation of Raf did result in estrogen-independent growth. In addition, the constitutively active Raf also induced apoptosis in these cells. In this study, we report that these Raf transfected cells growing long-term in the absence of estrogen have lost ER expression. This loss is at both the protein and RNA level. Potential mechanisms underlying this loss are discussed. In addition, we are assessing the role that known modulators of apoptosis may play in the Raf-induced apoptosis. After establishing conditions for Western blot analysis of the expression of these factors, we have examined two potentiators of apoptosis, Bax and Bad, and an inhibitor of cell cycle progression, WAF1/Cip1. There were no significant alterations in the expression levels of these proteins that could be correlated with either the presence of high levels of Raf kinase activity or with apoptosis in our clones.

14. SUBJECT TERMS Breast cancer; Estrogen-independent Growth; Signal Transduction; Raf-1 Kinase; Estrogen Receptor			**15. NUMBER OF PAGES** 19
			16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified	**18. SECURITY CLASSIFICATION OF THIS PAGE** Unclassified	**19. SECURITY CLASSIFICATION OF ABSTRACT** Unclassified	**20. LIMITATION OF ABSTRACT** Limited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

_____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

__✓__ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

_____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

_____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

__✓__ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Donaya El-Ashry 8/30/96
PI - Signature   **Date**

3

Table of Contents

INTRODUCTION

Breast cancer growth can be estrogen-dependent or -independent. Estrogen-dependent breast cancer, that is breast cancer that expresses functional estrogen receptors (ER) and requires estrogen for growth, has a better prognosis than estrogen-independent, ER-negative breast cancer (1-4). This better prognosis is reflected in both a longer disease-free survival and overall survival, as well as, response to endocrine therapies such as the anti-estrogen tamoxifen.

It is well established that estrogen treatment of ER+ breast cancer cells results in increased growth and the increased expression of several growth factors. As a result, it has long been hypothesized that estrogen promotes cellular proliferation via the induction of specific growth factors and their cognate receptors thus setting up an autocrine loop. Upon progression to estrogen-independent growth, there is loss of ER expression and overexpression of certain growth factors/receptors, such as TGF-α and EGFR. Given this, it is also possible that signal transduction via growth factor tyrosine kinase receptors is a separate and alternate pathway and thus a mechanism for bypassing estrogen-mediated effects. Upregulation of these pathways may therefore be an early event in progression to ER-, thus resulting in an intermediate ER+/estrogen-independent phenotype. Many studies support this idea. Breast cancer cells overexpressing FGF-4, FGF-1, or heregulin become tumorigenic in nude mice in the absence of estrogen (5,6). Overexpression of EGFR or erbB-2 in breast cancer cells confers a growth advantage in estrogen-depleted media (6-8) and can increase tumorigenesis in nude mice in the absence of estrogen.

One of the major pathways initiated by the EGFR ligands is the mitogen activated protein kinase (MAP kinase or MAPK) phosphorylation cascade [reviewed in (9)]. Upon binding of ligand, the activated receptor interacts with and activates Ras, resulting in the subsequent activation of the Raf protooncogene. Raf-1, one of three Rafs [reviewed in (10,11)], is a serine/threonine kinase that can directly phosphorylate nuclear transcription factors like p53 (12). It also activates MAP kinase kinase (MAPKK or MEK), a dual specificity kinase, which then activates MAPK. The activated MAPK, which is a serine/threonine kinase, is able to phosphorylate several nuclear transcription factors including Myc, Elk, and Rsk (13-18). It is now known that not only can the activated Ras oncogene cause cellular transformation (19,20), but that activated v-Raf or a constitutively activated MAPKK can also result in transformation (21-24). Furthermore, in a recent study of renal cell carcinomas, it was found that about 50% demonstrated upregulation of Raf, MEK, and MAPK (25), implicating this signal transduction pathway in the carcinogenic process.

We were interested in studying the role of Raf in human breast cancer for several reasons. First, overexpression of growth factor receptors such as EGFR and erbB-2 occurs in a significant percentage of breast tumors and is correlated with a poor prognosis. Such overexpression would be expected to have an effect on downstream factors. Second, there are several studies indicating that oncogenic Ras transfected into ER+ MCF-7 cells renders them estrogen-independent (26-30). While activating mutations of Ras are very rare in breast cancer, overexpression does occur in ~70% of breast cancer cases (31,32). This overexpression may have significant impact on the downstream effectors of Ras, such as Raf. A third reason to study Raf is that many other signaling systems such as protein kinase C (PKC) and protein kinase A (PKA) have been shown to activate or inactivate Raf respectively (33-35), suggesting that Raf may play a pivotal role in signal transduction by several different pathways known to be important in breast cancer.

5

We have previously reported on the stable transfection of a constitutively active Raf kinase (referred to as Δ-raf) into estrogen-dependent MCF-7 breast cancer cells. We had studied the growth growth characteristics of 6 Δ-raf clones arising from this transfection in comparison to the vector-transfected control pool of cell (referred to as Hcopool) and found that Δ-raf expression results in estrogen-independent growth, but the cells are responsive to estrogen (36). However, while the high Raf activity seems to allow for growth in the absence of estrogen, this high activity is not compatible with growth in the presence of estrogen and continued growth in estrogen-containing medium results in down-regulated expression of the transfected Raf. A second observation was that high levels of Raf activity in these cells leads to apoptosis as measured by an assay (refer to previous annual report) that specifically measures apoptosis by assessing the presence of histone-bound DNA fragments in the cytoplasm of cells -- a hallmark of apoptosis that distinguishes it from necrosis or other types of cell death. This apoptosis most likely is a result of the extremely high levels of constitutively active kinase in these cells, however we can use this as a model to study apoptotic pathways in breast cancer cells.

The objectives for the past year were to assess the mechanism by which Raf induced estrogen-independent growth, and to begin to assess the role that known effectors and modulators of apoptosis play in the Raf-induced apoptosis in our transfectants.

RESULTS

Estrogen and Anti-estrogen effects on Δ-raf clones growing long-term in the absence of estrogen (CCS). We had previously analyzed the growth of Δ-raf clones in the short-term absence of estrogen, and as shown previously, these clones were capable of estrogen-independent growth but were still responded to estrogen with further increased growth. Since then, we now had each of the clones growing long-term in the absence of estrogen [IMEM without phenol red supplemented with 10% charcoal-stripped serum (CCS)]. In order to begin to dissect the mechanism of Raf-induced estrogen-independent growth in our transfectants, we therefore assessed the growth capabilities and response to estrogen and anti-estrogens of these clones growing long-term in the absence of estrogen. Figure 1A represents results from an anchorage-dependent growth assay of HCopool (the vector-transfected control pool of MCF-7 cells that normally grow in FBS and for this experiment have been quick-stripped of estrogen and assayed for growth in CCS conditions), MCNC4 (a vector-transfected control clone of MCF-7 cells long-term adapted for growth in the absence of estrogen, and Raf 14c (a Δ-raf transfected clone of MCF-7 cells growing long-term in CCS). As shown, HCopool exhibits no significant growth in CCS after the first two days of the assay (since the cells have been quick-stripped and some residual estrogens initially remain, there is a short lag before the cells stop growing). The anti-estrogens tamoxifen and ICI 182 780 have no significant impact, however, the addition of estrogen or growth in FBS restores the growth capacity of these cells. MCNC4 cells are capable of slow growth in CCS, and this growth is slightly reduced in the presence of the anti-estrogens. Both estrogen and FBS are capable of inducing growth of these cells. Interestingly, the Δ-raf transfected clone, Raf 14c, exhibits growth not only in the absence of estrogen (CCS), but also in the presence of either anti-estrogen. Furthermore, the addition of estrogen or growth in FBS does not further increase the growth capacity of these cells. Thus the Δ-raf transfected cells growing long-term in the absence of estrogen no longer seem to respond to

6

estrogen.

Anchorage-independent growth in soft agar, a more stringent test of growth capacity, was next assessed. As shown in Figure 1B, Raf 14c produces a large number of colonies in CCS, about 650, compared to the ~ 50 colonies that quick-stripped HCopool produces. Again, while HCopool is responsive to estrogen, in that estrogen induces colony formation (~ 3-fold induction), and the anti-estrogens have a slightly inhibitory or no effect, Raf 14c produces the same high number of colonies under all conditions -- that is there is no response to either estrogen or the anti-estrogens. These unexpected results seemed to indicate that these cells were no longer expressing a functional ER.

Δ-raf Clones Growing Long-term in CCS Have Lost ER. To determine if this was indeed the case, Δ-raf clones were assessed for ER levels, both at the protein and RNA level. ER protein was analyzed both by a steroid-binding assay, which will measure all ER capable of binding estrogen, and by Western blotting with an anti-ER monoclonal antibody, which will detect all immunogenic ER. Results from these assays are shown in Figure 2 where the steroid-binding assay results are expressed in fmol/mg protein in parenthesis beneath each lane of Western-blotted lysate. Compared to the MCNC4 control cell line, which exhibits ~206 fmol ER/mg protein, each of the Δ-raf clones has significantly reduced levels of ER expression, with Raf 14c, the clone growing in CCS the longest and the least responsive to estrogen and anti-estrogens, having only ~10 fmol/mg protein. Thus, all of the clones had reduced levels of ER protein expression.

RNase protection assays, shown in Figure 3, were performed to determine ER RNA levels in the clones. Compared to either the Hcopool (grow in FBS) or the MCNC4 (grow in CCS) control cells, the Δ-raf clones exhibited drastically reduced RNA levels, and again, Raf 14c was the most dramatic with virtually no detectable expression.

Loss of ER Expression is, in part, at the Level of Transcription. Since we have now recapitulated the clinical progression of breast cancer, that is from ER+ to ER-, for the first time in a laboratory model, an important next step is to determine the mechanism to this Δ-raf induced loss of ER. As a first step to try and determine the mechanism underlying this loss, we were next interested in determining if there was a transcriptional component to the reduction of ER in the clones. A nuclear run-on assay was performed to assess the level of transcription of the ER gene in Raf 14c cells and in the control MCNC4 cell line (Figure 4). Raf 14c cells displayed a 7-fold reduction in transcription of ER as compared to that occurring in MCNC4 cells indicating that decreased transcription of the gene played a role in the significantly reduced levels of ER observed in these cells.

Assessment of the Expression of Known Modulators of Apoptosis. Since Δ-raf also induced apoptosis, our other line of investigation is to dissect the mechanisms underlying this in order to gain an understanding of specific apoptosis pathways in breast cancer cells. As a first step, we have been further characterizing the Raf-induced apoptosis that occurs in our transfected cells. Initially, we wanted to confirm that what we were observing in these cells was truly apoptosis by a second method, the Tunel assay which measures the presence of fragmented DNA in the cytoplasm of cells by flow cytometry (FACS). In the Tunel Assay, both floating and adherent cells were collected and fixed. Following incubation with terminal deoxytransferase and fluorescein-labeled nucleotides, the cells were analyzed by FACS. The positive control, human leukemia cells treated with campothecin to produce ~30% apoptotic cells, show the expected second peak representative

7

of apoptotic cells (Figure 5A). The negative controls, HCopool, HCopool stripped of estrogen for 5 days, and HCopool adapted long-term to grow in CCS, all look very similar with a single peak of low fluorescence (Figure 5B). Since the Δ-raf transfectants undergo apoptosis at some constant rate, that is they are not treated with an apoptosis inducer, it did not seem likely that two distinct peaks would be seen. Rather, one would expect a single peak that is much broader or with a shoulder as compared to non-apoptotic cells. In fact, the peak obtained with raf14c is much broader and shifted to the right compared with HCopool cells adapted to grow in CCS (Figure 5C). Since we had previously observed that the floating cell population was enriched for apoptotic cells, we also assayed these cells by Tunel. And, although the cell number was low resulting in more scatter, a second distinct peak of higher fluorescence is evident (Figure 5D). Next, we were interested in determining if any alterations in the expression levels of factors known to potentiate or inhibit apoptosis had occurred in the Δ-raf clones. Therefore, we have spent some time working out conditions for Western blot analysis of the expression of Bax, Bcl-2, Bcl-X_L and Bcl-X_S, Bad, Myc, p53, and WAF1/Cip1. At this time, we have determined that there are no significant alterations in the levels of two potentiators of apoptosis, Bax and Bad. Nor is there any change in the expression of WAF1/Cip1, a cell cycle inhibitor that is induced by p53. Further analysis of the other factors is ongoing.

DISCUSSION

Given the importance of growth factor signaling systems in breast cancer progression and reports on the existence of cross-talk between these signaling systems and the estrogen receptor signaling system, we have been using constitutively active Raf as a model of upregulated growth factor signaling, whether this be by overexpressed EGFR or erbB-2, etc. to study the progression of breast cancer from estrogen-dependent growth to estrogen-independent growth. We have previously found that the expression of a constitutively active form of the Raf kinase in MCF-7 ER+ human breast cancer cells results in two phenomena. First, as we hypothesized, it induced estrogen independent growth of these cells, both anchorage-dependent and anchorage-independent. Second, and unexpectedly, it induced apoptosis in these cells. Our focus over the last year has been to begin to dissect the mechanisms underlying both of these phenomena. First, we are interested in determining whether Raf induction of estrogen-independent growth is via an ER-mediated mechanism or if it is via a mechanism that is separate from and bypasses ER. Second, we are interested in examining the potential role that several known modulators of apoptosis in other cell systems play in the Raf-induced apoptosis.

To accomplish the first goal, we wanted to use Δ-raf transfected clones that had been growing long-term in the absence of estrogen (i.e. complete estrogen-independent growth). Before using these cells in experiments, we characterized their growth capabilities in the presence and absence of estrogen or anti-estrogens. Interestingly, in addition to the fact that these cells grew in the absence of estrogen, they no longer responded positively to the addition of estrogen nor did they respond to anti-estrogens as the control cells do. These data suggested that the cells no longer expressed a functional estrogen receptor. Analysis of the cells for ER expression at the levels of steroid-binding, overall protein, and RNA all confirmed the significant reduction in ER expression suggested above. These data are quite exciting because in all other transfections of growth factor signaling

components, i.e. EGFR, erbB-2, or Ras, the cells retained ER expression in spite of estrogen-independent growth. Thus, this is the first system described where the chronic activation of growth signaling pathways has resulted in both estrogen-independent growth and loss of ER. This ER loss could be by one of two mechanisms. First, if Raf activation of the MAPK kinase cascade activates ER in the absence of estrogen (ligand-independent activation), then it is likely that the constitutive activation that occurs in our cells would result in the constitutive activation of ER. And since an end result of ER activation by estrogen is its eventual down-regulation, a constitutive and unending activation of ER would ultimately result in the chronic and total down-regulation of ER. Alternatively, Raf induction of estrogen-independent growth could be via an ER-independent mechanism and the progressive loss of ER in our cells could merely be due to the fact that since the cells no longer need ER for growth, they have down-regulated its expression. We have preliminary data suggesting that the high levels of apoptosis which we originally observed in these cells has decreased along with the decrease in ER expression. We are currently analyzing whether these are linked phenomena or unrelated events. Additionally, we are focusing on determining which of the two above possibilities are responsible for the ER loss. We are currently analyzing the expression of estrogen-induced genes and determining if the ER loss is reversible or if its permanent. And finally, since the expression of the constitutively active Raf in these cells has such strong effects that the cells are continuously going through adaptive processes and changing (i.e. the loss of Raf expression when the transfectants are grown in FBS in our original report, or the decrease of ER expression and apoptosis as described here), our immediate focus is to re-transfect MCF-7 cells with an inducible and regulatable Raf kinase construct. This system, the tetracycline-repressible system, will allow us to specifically turn on Raf kinase expression and immediately assess the effects of its activity.

REFERENCES

1. Knight, W.A., Livingston, R.B., Gregory, E.J., and McGuire, W.L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. *37*: 4669-4671, 1977.

2. De Sombre, E.R., Thorpe, S.M., Rose, C., Blough, R.R., Andersen, K.W., Rasmussen, B.B., and King, W.J. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res. *46*: 4256s-4264s, 1986.

3. Clark, G.M. and McGuire, W.L. Steroid receptors and other prognostic factors in primary breast cancer. Semin. Oncol. *15*: 20-25, 1988.

4. McGuire, W.L., Tandon, A.K., Allred, D.C., Chamness, G.C., and Clark, G.M. How to use prognostic factors in axillary node-negative breast cancer patients [see comments]. J. Natl. Cancer Inst. *82*: 1006-1015, 1990.

5. McLeskey, S.W., Kurebayashi, J., Honig, S.F., Zwiebel, J., Lippman, M.E., Dickson, R.B., and Kern, F.G. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res. *53*: 2168-2177, 1993.

6. Pietras, R.J., Arboleda, J., Reese, D.M., Wongvipat, N., Pegram, M.D., Ramos, L., Gorman, C.M., Parker, M.G., Sliwkowski, M.X., and Slamon, D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, *10*: 2435-2446, 1995.

7. Miller, D.L., El-Ashry, D., Cheville, A.L., Liu, Y., McLeskey, S.W., and Kern, F.G. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ. *5*: 1263-1274, 1994.

8. Liu, Y., El-Ashry, D., Chen, D., Ding, I.Y.F., and Kern, F.G. MCF-7 breast cancer cells overexpressing transfected *c-erb*B-2 have an *in vitro* growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity *in vivo*. Breast Cancer Research and Treatment, *34*: 97-117, 1995.

9. Hill, C.S. and Treisman, R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell, *80*: 199-211, 1995.

10. Li, P., Wood, K., Mamon, H., Haser, W., and Roberts, T. Raf-1: a kinase currently without a cause but not lacking in effects. Cell, *64*: 479-482, 1991.

11. Magnuson, N.S., Beck, T., Vahidi, H., Hahn, H., Smola, U., and Rapp, U.R. The Raf-1 serine/threonine protein kinase. Semin. Cancer Biol. *5*: 247-253, 1994.

12. Jamal, S. and Ziff, E.B. Raf phosphorylates p53 *in vitro* and potentiates p53-dependent transcriptional activation *in vivo*. Oncogene, *10*: 2095-2101, 1995.

13. Siegfried, Z. and Ziff, E.B. Altered transcriptional activity of c-Fos promoter plasmids in v-Raf-transformed NIH 3T3 cells. Mol. Cell Biol. *10*: 6073-6078, 1990.

14. Kolch, W., Heidecker, G., Lloyd, P., and Rapp, U.R. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature, *349*: 426-428, 1991.

15. Alexandropoulos, K., Qureshi, S.A., Bruder, J.T., Rapp, U., and Foster, D.A. The induction of EGR-1 expression by v-FPS is via a protein kinase C-independent intracellular signal that is sequentially dependent upon HaRas and Raf-1. Cell Growth Differ. *3*: 731-737, 1992.

16. Blenis, J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. U. S. A. *90*: 5889-5892, 1993.

17. Thomas, G. MAP kinase by any other name smells just as sweet. Cell, *68*: 3-6, 1992.

18. Crews, C.M., Alessandrini, A., and Erikson, R.L. Erks: their fifteen minutes has arrived. Cell Growth Differ. *3*: 135-142, 1992.

19. Barbacid, M. Ras genes. Annu. Rev. Biochem. *56*: 779-827, 1987.

20. Trahey, M., Milley, R.J., Cole, G.E., Innis, M., Paterson, H., Marshall, C.J., Hall, A., and McCormick, F. Biochemical and biological properties of the human n-Ras p21 protein. Mol. Cell Biol. *7*: 541-544, 1987.

21. Heidecker, G., Huleihel, M., Cleveland, J.L., Kolch, W., Beck, T.W., Lloyd, P., Pawson, T., and Rapp, U.R. Mutational activation of c-Raf-1 and definition of the minimal transforming sequence. Mol. Cell Biol. *10*: 2503-2512, 1990.

22. Cleveland, J.L., Troppmair, J., Packham, G., Askew, D.S., Lloyd, P., Gonzalez-Garcia, M., Nunez, G., Ihle, J.N., and Rapp, U.R. V-Raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene, *9*: 2217-2226, 1994.

23. Samuels, M.L., Weber, M.J., Bishop, J.M., and McMahon, M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol- dependent human Raf-1 protein kinase. Mol. Cell Biol. *13*: 6241-6252, 1993.

24. Mansour, S.J., Matten, W.T., Hermann, A.S., Candia, J.M., Rong, S., Fukasawa, K., Vande

11

Woude, G.F., and Ahn, N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science, 265: 966-970, 1994.

25. Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., and Yoshida, O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55: 4182-4187, 1995.

26. Dickson, R.B., Kasid, A., Huff, K.K., Bates, S.E., Knabbe, C., Bronzert, D., Gelmann, E.P., and Lippman, M.E. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-Ras oncogene. Proc. Natl. Acad. Sci. U. S. A. 84: 837-841, 1987.

27. Sukumar, S., Carney, W.P., and Barbacid, M. Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science, 240: 524-526, 1988.

28. Kasid, A., Lippman, M.E., Papageorge, A.G., Lowy, D.R., and Gelmann, E.P. Transfection of v-RasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science, 228: 725-728, 1985.

29. Kasid, A., Knabbe, C., and Lippman, M.E. Effect of v-RasH oncogene transfection on estrogen-independent tumorigenicity of estrogen-dependent human breast cancer cells. Cancer Res. 47: 5733-5738, 1987.

30. Sommers, C.L., Papageorge, A., Wilding, G., and Gelmann, E.P. Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of RasH. Cancer Res. 50: 67-71, 1990.

31. Ohuchi, N., Thor, A., Page, D.L., Hand, P.H., Halter, S.A., and Schlom, J. Expression of the 21,000 molecular weight Ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res. 46: 2511-2519, 1986.

32. Thor, A., Ohuchi, N., Hand, P.H., Callahan, R., Weeks, M.O., Theillet, C., Lidereau, R., Escot, C., Page, D.L., Vilasi, V., and et al Ras gene alterations and enhanced levels of Ras p21 expression in a spectrum of benign and malignant human mammary tissues. Lab. Invest. 55: 603-615, 1986.

33. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U.R. Protein kinase C alpha activates Raf-1 by direct phosphorylation. Nature, 364: 249-252, 1993.

34. Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weber, M.J., and Sturgill, T.W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate [see comments]. Science, 262: 1065-1069, 1993.

35. Vaillancourt, R.R., Gardner, A.M., and Johnson, G.L. B-Raf-dependent regulation of the

MEK-1/mitogen-activated protein kinase pathway in PC12 cells and regulation by cyclic AMP. Mol. Cell Biol. *14*: 6522-6530, 1994.

36. El-Ashry, D., Miller, D.L., Kharbanda, S., Lippman, M.E., and Kern, F.G. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene, in revision, 1996.

Figure Legends

Figure 1. Growth response of Raf14c to estrogen and anti-estrogens. A. HCopool cells were quick-stripped to remove estrogens. 10,000 cells were plated into triplicate 24-well plates in CCS, treated with various hormones, and counted every 2 days. Values represent the average of the triplicates with error bars indicating the standard error. The X-axis represents time in days, and the Y-axis represents cell number. **B.** 20,000 cells (HCopool was quick-stripped) were plated in triplicate in CCS + 0.36% agar onto a bottom layer consisting of CCS + 0.6% agar. Plates were counted at 9 days after plating, and values represent the average of the triplicates with the standard error indicated by error bars.

Figure 2. Long-term growth in CCS results in loss of ER protein. Whole cell extracts were prepared from cells and analyzed by Western blotting and by steroid-binding assay. For Western blots, extracts (150 μg) were electrophoresed through 10% polyacrylamide gels, transferred, and probed with an anti-ER monoclonal antibody prepared against the hinge region of ER. For steroid binding assay, extracts were incubated with 10^{-8} M ^{3}H-estradiol plus or minus a 100-fold excess of cold, unlabeled estradiol as competitor. Unbound ligand was removed by incubating with dextran-coated charcoal, and bound receptors were quantitated by counting samples in a Beckman Scintillation Counter. Receptor number is expressed as fmol/mg protein.

Figure 3. Long-term growth in CCS results in loss of ER mRNA. RNA from Hcopool, MCNC4, MDA-231 (an ER negative control), and the Δ-raf clones was analyzed by RNase protection for expression of ER (top panel) and GAPDH loading control (bottom panel). Migration of molecular weight markers is shown in the first and last lanes, and undigested antisense riboprobes is shown in the second lane. For each Δ-raf clone, FBS refers to cells growing long-term in FBS, CCSe and CCSl refer to long-term growth in CCS for a shorter time (e) or longer time (l).

Figure 4. Reduced transcription of ER in raf14c cells. Nuclei were isolated from the MCNC4 and raf14c cells and nuclear run-on assays were performed. Labeled RNA was hybridized to the immobilized DNA probes (genomic ER and 36B4 as a normalization control). The blot was analyzed and quantitated with a phosphoimager (Molecular Dynamics), and the values for ER were normalized to 36B4.

Figure 5. Confirmation of Apoptosis by Tunel Assay. Cells were fixed in 1% paraformaldehyde, incubated with Tdt and fluorescein-labeled nucleotides, and analyzed by FACS as described. **A.** Positive control cells consisting of human leukemia cells treated for 24 hrs with campothecin to induce ~30% apoptotic cells (left). **B.** Negative control cells consisting of HCopool, HCopool stripped of estrogen for 5 days, and HCopool adapted to grow long-term in CCS (right). **C.** HCopool cells adapted for growth in CCS and total raf14c cell population (floaters and adherents). **D.** Raf14c floater population only.

Figure 1

# Loss of Estrogen Response after Long-term Growth in CCS

Figure 2

# Long-term Growth in CCS Results in Loss of ER Protein

Figure 3

Long-term Growth in CCS Results in Loss of ER mRNA

Figure 4

Reduced Transcription of ER in raf14c Cells

Figure 5

Confirmation of Apoptosis by Tunel Assay

REPLY TO
ATTENTION OF:

MCMR-RMI-S   (70-1y)   6 May 98

MEMORANDUM FOR Administrator, Defense Technical Information
              Center, ATTN: DTIC-OCP, Fort Belvoir,
              VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has
reexamined the need for the limitation assigned to technical
reports written for the following contracts. Request the
limited distribution statement for these contracts be changed
to "Approved for public release; distribution unlimited." These
reports should be released to the National Technical Information
Service.

Contract Number	Accession Document Number
DAMD17-94-J-4030	ADB215484
DAMD17-94-J-4138	ADB215863
DAMD17-94-J-4158	ADB215553
DAMD17-94-J-4278	ADB215864
DAMD17-94-J-4267	ADB216187
DAMD17-94-J-4200	ADB216054
DAMD17-94-J-4185	ADB219284
DAMD17-94-J-4172	ADB224562
DAMD17-94-J-4156	ADB216186
DAMD17-94-J-4082	ADB215979
DAMD17-94-J-4053	ADB216052
DAMD17-94-J-4028	ADB218953

2. Point of contact for this request is Ms. Betty Nelson at
DSN 343-7328 or email: betty_nelson@ftdetrck-ccmail.army.mil.

FOR THE COMMANDER:

PHYLIS M. RINEHART
Deputy Chief of Staff for
Information Management